Page last updated: 2024-10-20

pteridines and HIV Infections

pteridines has been researched along with HIV Infections in 8 studies

HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (37.50)	24.3611
2020's	4 (50.00)	2.80

Authors

Authors	Studies
Ram, RR	1
Duatschek, P	1
Margot, N	1
Abram, M	1
Geleziunas, R	3
Hesselgesser, J	2
Callebaut, C	1
Martinsen, JT	1
Gunst, JD	1
Højen, JF	1
Tolstrup, M	1
Søgaard, OS	1
Riddler, SA	1
Para, M	1
Benson, CA	1
Mills, A	2
Ramgopal, M	2
DeJesus, E	2
Brinson, C	2
Cyktor, J	1
Jacobs, J	1
Koontz, D	1
Mellors, JW	1
Laird, GM	2
Wrin, T	2
Patel, H	1
Guo, S	2
Wallin, J	1
Boice, J	1
Zhang, L	2
Humeniuk, R	2
Begley, R	2
German, P	1
Graham, H	1
Brainard, DM	2
SenGupta, D	2
Shalit, P	1
Cai, Y	1
Wallin, JJ	1
Mellors, J	1
Jones, N	1
Milush, J	1
Ferre, AL	1
Shacklett, BL	1
Moldt, B	1
Vendrame, E	1
Deeks, SG	1
Macedo, AB	1
Novis, CL	1
De Assis, CM	1
Sorensen, ES	1
Moszczynski, P	1
Huang, SH	1
Ren, Y	1
Spivak, AM	1
Jones, RB	1
Planelles, V	1
Bosque, A	1
Bam, RA	1
Hansen, D	1
Irrinki, A	2
Mulato, A	1
Jones, GS	1
Frey, CR	1
Cihlar, T	2
Yant, SR	1
Tsai, A	1
Kaur, J	1
Kukolj, G	1
Sloan, DD	1
Murry, JP	1
Baier-Bitterlich, G	1
Wachter, H	1
Fuchs, D	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults[NCT02858401]			Phase 1	48 participants (Actual)	Interventional	2015-01-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 101

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 101. (NCT02858401)
Timeframe: Baseline; Day 101

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.02
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.05

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 106

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 106. (NCT02858401)
Timeframe: Baseline; Day 106

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.10

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 11

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 11. (NCT02858401)
Timeframe: Baseline; Day 11

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 113

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 113. (NCT02858401)
Timeframe: Baseline; Day 113

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.09

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 115

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 115. (NCT02858401)
Timeframe: Baseline; Day 115

Intervention	Log10 copies/mL (Mean)
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.08

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 120

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 120. (NCT02858401)
Timeframe: Baseline; Day 120

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.04
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.01

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 127

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 127. (NCT02858401)
Timeframe: Baseline; Day 127

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 128

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 128. (NCT02858401)
Timeframe: Baseline; Day 128

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.06

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 129

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 129. (NCT02858401)
Timeframe: Baseline; Day 129

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.03

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 134

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 134. (NCT02858401)
Timeframe: Baseline; Day 134

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.09

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 15

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 15. (NCT02858401)
Timeframe: Baseline; Day 15

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 157

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 157. (NCT02858401)
Timeframe: Baseline; Day 157

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.13

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 17

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 17. (NCT02858401)
Timeframe: Baseline; Day 17

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.01
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 19

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 19. (NCT02858401)
Timeframe: Baseline; Day 19

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 2

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 2. (NCT02858401)
Timeframe: Baseline; Day 2

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 22

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 22. (NCT02858401)
Timeframe: Baseline; Day 22

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.02
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 25

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 25. (NCT02858401)
Timeframe: Baseline; Day 25

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 29

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 29. (NCT02858401)
Timeframe: Baseline; Day 29

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.01
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.02
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 3

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 3. (NCT02858401)
Timeframe: Baseline; Day 3

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.00
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.01

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 31

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 31. (NCT02858401)
Timeframe: Baseline; Day 31

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 33

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 33. (NCT02858401)
Timeframe: Baseline; Day 33

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Placebo	0.01

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 36

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 36 (NCT02858401)
Timeframe: Baseline; Day 36

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.16

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 39

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 39 (NCT02858401)
Timeframe: Baseline; Day 39

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.04
Placebo	0.25

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 43

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 43 (NCT02858401)
Timeframe: Baseline; Day 43

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 45

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit pn Day 45 (NCT02858401)
Timeframe: Baseline; Day 45

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 47

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 47 (NCT02858401)
Timeframe: Baseline; Day 47

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.07
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 5

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 5. (NCT02858401)
Timeframe: Baseline; Day 5

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 50

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 50. (NCT02858401)
Timeframe: Baseline; Day 50

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 53

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 53 (NCT02858401)
Timeframe: Baseline; Day 53

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.01
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 57

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 57. (NCT02858401)
Timeframe: Baseline; Day 57

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.03
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.03

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 58

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 58. (NCT02858401)
Timeframe: Baseline; Day 58

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 59

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 59. (NCT02858401)
Timeframe: Baseline; Day 59

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.01
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.07

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 61

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 61. (NCT02858401)
Timeframe: Baseline; Day 61

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.01
Placebo	0.03

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 64

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 64. (NCT02858401)
Timeframe: Baseline; Day 64

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.07
Vesatolimod 2 mg (Cohort 2)	0.01
Vesatolimod 4 mg (Cohort 3)	0.07
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.02
Placebo	0.02

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 67

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 67. (NCT02858401)
Timeframe: Baseline; Day 67

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.04
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 71

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 71. (NCT02858401)
Timeframe: Baseline; Day 71

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.02
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.02
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 73

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 73. (NCT02858401)
Timeframe: Baseline; Day 73

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	0.01
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.04

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 75

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 75. (NCT02858401)
Timeframe: Baseline; Day 75

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 78

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 78. (NCT02858401)
Timeframe: Baseline; Day 78

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.19

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 8

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 8. (NCT02858401)
Timeframe: Baseline; Day 8

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 81

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 81. (NCT02858401)
Timeframe: Baseline; Day 81

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.00
Vesatolimod 2 mg (Cohort 2)	0.00
Vesatolimod 4 mg (Cohort 3)	-0.03
Placebo	0.00

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 85

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 85. (NCT02858401)
Timeframe: Baseline; Day 85

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.03

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 87

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 87. (NCT02858401)
Timeframe: Baseline; Day 87

Intervention	Log10 copies/mL (Mean)
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.19

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 92

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 92. (NCT02858401)
Timeframe: Baseline; Day 92

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.00
Placebo	0.11

Change From Baseline in Plasma Log10 HIV-1 RNA at Day 99

Change from baseline in plasma log10 HIV-1 RNA refers to change from baseline at a postbaseline visit on Day 99. (NCT02858401)
Timeframe: Baseline; Day 99

Intervention	Log10 copies/mL (Mean)
Vesatolimod 6 mg (Cohort 4)	0.00
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.03
Placebo	0.07

Maximum Change From Baseline in Plasma Log10 HIV-1 RNA at Any Postdose Timepoint

The maximum change from baseline in plasma Log10 HIV-1 RNA refers to the maximum change at any postdose timepoint up to Day 81 or Day 134 for placebo, Day 81 for Cohorts 1 to 3, and Day 134 for Cohorts 4 to 6. (NCT02858401)
Timeframe: For Cohorts 1 to 3: Baseline to Day 81; For Cohorts 4 to 6: Baseline to Day 134; For placebo: Baseline to Day 81 or Baseline to Day 134

Intervention	Log10 copies/mL (Mean)
Vesatolimod 1 mg (Cohort 1)	0.06
Vesatolimod 2 mg (Cohort 2)	0.01
Vesatolimod 4 mg (Cohort 3)	0.10
Vesatolimod 6 mg (Cohort 4)	0.04
Vesatolimod 8 mg (Cohort 5)	0.00
Vesatolimod 10 or 12 mg (Cohort 6)	0.07
Placebo	0.42

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at Postdose 1 on Day 1

(NCT02858401)
Timeframe: Postdose 1 on Day 1

Intervention	percentage of participants (Number)
Vesatolimod 1 mg (Cohort 1)	0.0
Vesatolimod 2 mg (Cohort 2)	0.0
Vesatolimod 4 mg (Cohort 3)	0.0
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	0.0

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 10 on Day 127

(NCT02858401)
Timeframe: PostDose 10 on Day 127

Intervention	percentage of participants (Number)
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	16.7

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 2 on Day 15

(NCT02858401)
Timeframe: PostDose 2 on Day 15

Intervention	percentage of participants (Number)
Vesatolimod 1 mg (Cohort 1)	0.0
Vesatolimod 2 mg (Cohort 2)	0.0
Vesatolimod 4 mg (Cohort 3)	0.0
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	0.0

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 3 on Day 29

(NCT02858401)
Timeframe: PostDose 3 on Day 29

Intervention	percentage of participants (Number)
Vesatolimod 1 mg (Cohort 1)	0.0
Vesatolimod 2 mg (Cohort 2)	0.0
Vesatolimod 4 mg (Cohort 3)	0.0
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	8.3

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 4 on Day 43

(NCT02858401)
Timeframe: PostDose 4 on Day 43

Intervention	percentage of participants (Number)
Vesatolimod 1 mg (Cohort 1)	0.0
Vesatolimod 2 mg (Cohort 2)	0.0
Vesatolimod 4 mg (Cohort 3)	16.7
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	0.0

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 5 on Day 57

(NCT02858401)
Timeframe: PostDose 5 on Day 57

Intervention	percentage of participants (Number)
Vesatolimod 1 mg (Cohort 1)	0.0
Vesatolimod 2 mg (Cohort 2)	0.0
Vesatolimod 4 mg (Cohort 3)	16.7
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	9.1

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 6 on Day 71

(NCT02858401)
Timeframe: PostDose 6 on Day 71

Intervention	percentage of participants (Number)
Vesatolimod 1 mg (Cohort 1)	0.0
Vesatolimod 2 mg (Cohort 2)	0.0
Vesatolimod 4 mg (Cohort 3)	0.0
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	9.1

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 7 on Day 85

(NCT02858401)
Timeframe: PostDose 7 on Day 85

Intervention	percentage of participants (Number)
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	16.7

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 8 on Day 99

(NCT02858401)
Timeframe: PostDose 8 on Day 99

Intervention	percentage of participants (Number)
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	16.7

Percentage of Participants With Plasma HIV-1 RNA ≥ 50 Copies/mL at PostDose 9 on Day 113

(NCT02858401)
Timeframe: PostDose 9 on Day 113

Intervention	percentage of participants (Number)
Vesatolimod 6 mg (Cohort 4)	0.0
Vesatolimod 8 mg (Cohort 5)	0.0
Vesatolimod 10 or 12 mg (Cohort 6)	0.0
Placebo	0.0

Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and Any Treatment-Emergent Adverse Events (AEs).

(NCT02858401)
Timeframe: For Cohorts 1 to 3: First dose date up to 71 days plus 30 days; For Cohorts 4 to 6: First dose date up to 127 days plus 30 days; For placebo: First dose date up to 71 days plus 30 days or first dose date up to 127 days plus 30 days

,,,,,,

Intervention	percentage of participants (Number)
	SAEs	AEs
Placebo	0.0	75.0
Vesatolimod 1 mg (Cohort 1)	0.0	66.7
Vesatolimod 10 or 12 mg (Cohort 6)	0.0	66.7
Vesatolimod 2 mg (Cohort 2)	16.7	66.7
Vesatolimod 4 mg (Cohort 3)	0.0	33.3
Vesatolimod 6 mg (Cohort 4)	0.0	66.7
Vesatolimod 8 mg (Cohort 5)	0.0	83.3

Reviews

1 review available for pteridines and HIV Infections

Article	Year
The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. Frontiers in immunology, 2020, Volume: 11 Topics: Adjuvants, Immunologic; AIDS Vaccines; Animals; Anti-HIV Agents; Broadly Neutralizing Antibodies; Cl	2020

Trials

2 trials available for pteridines and HIV Infections

Article	Year
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 06-01, Volume: 72, Issue:11 Topics: Antiviral Agents; Double-Blind Method; HIV Infections; HIV-1; Humans; Pteridines; Toll-Like Receptor	2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Science translational medicine, 2021, 06-23, Volume: 13, Issue:599 Topics: Animals; Anti-Retroviral Agents; HIV Infections; Humans; Pteridines; Simian Acquired Immunodeficienc	2021

Other Studies

5 other studies available for pteridines and HIV Infections

Article	Year
Activation of HIV-specific CD8 Antiviral therapy, 2020, Volume: 25, Issue:3 Topics: Anti-HIV Agents; CD8-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Flow Cytometry; HIV;	2020
Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI insight, 2018, 10-04, Volume: 3, Issue:19 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dendritic Cells; Drug Evaluati	2018
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:1 Topics: Antibodies; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; HIV Infections	2017
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. Journal of virology, 2017, 04-15, Volume: 91, Issue:8 Topics: Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; CD8-Positive T-Lymphocytes; Cell Diffe	2017
Oxidative stress and apoptosis in HIV infection. Science (New York, N.Y.), 1996, Feb-02, Volume: 271, Issue:5249 Topics: Apoptosis; Biopterins; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Neopterin; Oxidati	1996